Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
KERX [NASD]
Keryx Biopharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own1.29% Shs Outstand81.72M Perf Week-2.19%
Market Cap657.03M Forward P/E44.67 EPS next Y0.18 Insider Trans0.96% Shs Float80.42M Perf Month5.65%
Income-25.36M PEG- EPS next Q-0.09 Inst Own53.36% Short Float20.96% Perf Quarter17.89%
Sales0.00M P/S- EPS this Y15.93% Inst Trans111.11% Short Ratio5.62 Perf Half Y215.29%
Book/sh0.15 P/B53.60 EPS next Y132.30% ROA-81.73% Target Price12.63 Perf Year310.20%
Cash/sh0.18 P/C44.76 EPS next 5Y30.00% ROE-122.10% 52W Range1.50 - 9.98 Perf YTD206.87%
Dividend- P/FCF- EPS past 5Y0.00% ROI-114.62% 52W High-19.44% Beta3.81
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low436.00% ATR0.38
Employees25 Current Ratio1.88 Sales Q/Q- Oper. Margin- RSI (14)50.54 Volatility5.06% 4.65%
OptionableYes Debt/Eq0.00 EPS Q/Q24.08% Profit Margin- Rel Volume0.57 Prev Close8.00
ShortableYes LT Debt/Eq0.00 EarningsMay 08 BMO Payout- Avg Volume3.00M Price8.04
Recom1.50 SMA20-1.30% SMA504.77% SMA20081.12% Volume1,725,670 Change0.50%
29-Jan-13Reiterated Stifel Nicolaus Buy $4 → $13
29-Jan-13Reiterated MLV & Co Buy $5 → $15
29-Jan-13Reiterated Ladenburg Thalmann Buy $5 → $15
29-Jan-13Reiterated Burrill Institutional Research Mkt Outperform $6 → $11
28-Jan-13Reiterated Maxim Group Buy $4 → $9
13-Dec-12Initiated Maxim Group Buy $4
13-Nov-12Initiated Burrill Institutional Research Mkt Outperform $6
10-Oct-12Reiterated Ladenburg Thalmann Buy $3 → $5
10-May-12Upgrade Ladenburg Thalmann Neutral → Buy $3
03-Apr-12Downgrade Ladenburg Thalmann Buy → Neutral
02-Apr-12Reiterated Brean Murray Buy $10 → $5
17-May-11Initiated Oppenheimer Outperform $7
06-May-11Initiated MLV Capital Buy $18
16-Mar-11Initiated JMP Securities Mkt Outperform $8
10-Mar-11Reiterated Ladenburg Thalmann Buy $9 → $10
12-May-10Reiterated Rodman & Renshaw Mkt Outperform $6 → $8
11-May-10Reiterated Ladenburg Thalmann Buy $5 → $8
01-Mar-10Initiated Rodman & Renshaw Mkt Outperform $6
25-Feb-10Initiated Roth Capital Buy $7
16-Mar-09Reiterated Brean Murray Buy $4 → $3
15-May-13 01:04PM  KERYX BIOPHARMACEUTICALS INC Financials EDGAR Online Financials
12-May-13 04:22PM  Earnings Volatility Drives These Stocks in a New Direction at Wall St. Cheat Sheet
11-May-13 11:06PM  Weekly Stock Watch - Week Of May 13, 2013 at Seeking Alpha
10-May-13 04:11PM  Short Interest Increases 10% For KERX at TheStreet
08-May-13 11:12PM  Keryx Biopharmaceutical's CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
05:01PM  3 Key Takeaways From Keryx's Earnings Report at Motley Fool
09:37AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
09:30AM  Keryx: A Small Biotech With Many Catalysts at Seeking Alpha
08:30AM  Keryx Biopharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today CCBN
08:19AM  Keryx Biopharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today CCBN
07:37AM  Keryx Biopharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today CCBN
07-May-13 05:49PM  Keryx Biopharmaceuticals Earnings: Heres Why Shares are Up Now at Wall St. Cheat Sheet
04:36PM  InPlay: Keryx Biopharma misses by $0.02, reports revs in-line Briefing.com
04:30PM  Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results PR Newswire
03:39PM  Whisper Number Impact: Earnings Preview For Keryx Biopharmaceuticals at Seeking Alpha
09:49AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06-May-13 04:30PM  Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013 Financial Results PR Newswire
02-May-13 01:16PM  Grab KERX 7.9% Cheaper Than Its Secondary? at Forbes
30-Apr-13 11:45AM  Low Cost of Capital, Revenue Replacement for Drugs That Lost Patent Protection are Major Drivers of M&A in the Pharma Space Wall Street Transcript
29-Apr-13 05:51AM  NewLink Genetics: Looking To Join The Industry's Largest Movers at Seeking Alpha
22-Apr-13 05:00PM  Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Health Care Winner at TheStreet
03:02PM  Keryx, Zerenex, And IP Protection: A PropThink Conference Call at Seeking Alpha
04:59AM  Keryx BioPharmaceuticals: A Favorite Of Mine In The Pharmacology World at Seeking Alpha
16-Apr-13 08:37PM  These Cutting-Edge Science Stocks Are Soaring at Motley Fool
14-Apr-13 03:54AM  Best Performing Russell 3,000 Stocks YTD at Seeking Alpha
12-Apr-13 04:22PM  3 Speculative Biotech Stocks to Buy Now at Motley Fool
01:21PM  Here Are The Reasons To Own Keryx And Why Catalysts Are De-Risked at Seeking Alpha
11-Apr-13 05:01PM  Today's Drugs Industry Featured Laggard: Keryx Biopharmaceuticals Inc. (KERX) at TheStreet
03:20PM  Six stocks to watch for some upside at MarketWatch
03:20PM  Six stocks to watch for some upside at MarketWatch
10-Apr-13 08:12AM  Today's Market News To Trade On: 5 Stocks Moving On News at Seeking Alpha
09-Apr-13 06:04PM  Nasdaq stocks posting largest percentage increases AP +10.35%
01:25PM  Nasdaq stocks posting largest percentage increases AP
12:18PM  [video] Bears Eat Herbalife, JC Penney - Bulls Find Keryx at TheStreet
12:18PM  [video] Bears Eat Herbalife, J.C. Penney; Bulls Find Keryx at TheStreet
08-Apr-13 10:27AM  What You Need To Know About Keryx And Zerenex's IP at Seeking Alpha
07:47AM  Biotech's Fallen Angels: Identifying Irrational Market Behavior at Seeking Alpha
05-Apr-13 02:00PM  3 Stellar Drugs Equal 3 Attractive Buying Opportunities at Motley Fool
04-Apr-13 02:50PM  [video] '100% Club' Stocks for 2013 at CNBC
09:48AM  3 Speculative Biotech Companies Primed to Pop at Motley Fool
01-Apr-13 03:28PM  A Pair of Stocks With an Amazing Quarter at Motley Fool
29-Mar-13 02:12AM  Are Any Of Your Stocks Members Of The Triple Digit Club? at Seeking Alpha
28-Mar-13 05:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- KERX GlobeNewswire
26-Mar-13 09:02PM  Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Here at Seeking Alpha
05:01PM  Keryx Biopharmaceuticals Inc. (KERX): Health Care's Highlighted Dud Of The Day at TheStreet
25-Mar-13 06:51PM  Here's What This $3 Billion Market Wizard Has Been Buying at Motley Fool
04:02PM  These 4 Biotech Stocks Have Upside, Says Burrill's Senior Analyst at Seeking Alpha
08:11AM  SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position Business Wire
22-Mar-13 06:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- KERX GlobeNewswire
21-Mar-13 03:43PM  Rockwell May Rise On Positive Phase III Results In July at Seeking Alpha
20-Mar-13 04:58PM  The Validity And Risk Of Keryx Biopharmaceuticals at Seeking Alpha
19-Mar-13 07:52PM  Down 60%: Affymax Cuts to the Bone at Motley Fool
06:39PM  SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position PR Newswire
18-Mar-13 10:34PM  Here's What This 220% Gainer Has Been Buying and Selling at Motley Fool
08:30PM  Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Keryx Biopharmaceuticals, Inc. to Contact the Firm -- KERX GlobeNewswire
05:12PM  SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position Business Wire
02:45PM  5 Investing Tricks Of The Trade For Your Arsenal at Seeking Alpha
16-Mar-13 01:04PM  KERYX BIOPHARMACEUTICALS INC Financials EDGAR Online Financials
15-Mar-13 01:04PM  KERYX BIOPHARMACEUTICALS INC Financials EDGAR Online Financials
14-Mar-13 08:56AM  Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference PR Newswire
13-Mar-13 02:55PM  Zerenex Patent Protection Is Key For Keryx Upside, But EU Exclusivity Provides A Base at Seeking Alpha
08:30AM  Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs PR Newswire
07:37AM  Keryx CEO vs. a Short-Seller: Zerenex Patent Debate at TheStreet
07:37AM  Keryx CEO vs. A Short Seller: Zerenex Patent Debate at TheStreet
12-Mar-13 09:30PM  20 Small-Cap Stocks to Sell Immediately The StreetAuthority Network
09:30PM  20 Small-Cap Stocks to Sell Immediately
08:32PM  New Star Analyst Rankings for Keryx Biopharmaceuticals, Inc. StarMine
08:15PM  20 Small-Cap Stocks to Sell Immediately The StreetAuthority Network
08:15PM  20 Small-Cap Stocks to Sell Immediately
06:15PM  20 Small-Cap Stocks to Sell Immediately The StreetAuthority Network
06:15PM  20 Small-Cap Stocks to Sell Immediately
03:34PM  Keryx Biopharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha
08:30AM  Keryx Biopharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today CCBN
07:07AM  Q4 2012 Keryx Biopharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
06:03AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
11-Mar-13 05:52PM  Breakdown of This Biotech Massacre at Motley Fool
05:36PM  InPlay: Keryx Biopharma reports Q4 results Briefing.com
04:30PM  Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results PR Newswire
03:17PM  Companies reporting Before the Market Open on Tuesday, March 12 at theflyonthewall.com
09:33AM  Cramer: Sell Krispy Kreme Doughnuts and These 3 Stocks, Buy Oaktree Capital at Wall St. Cheat Sheet
08:30AM  Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results PR Newswire
08-Mar-13 07:24PM  Steer Clear of Affymax's Mysterious Pop at Motley Fool
06:49PM  Cramer's Homework: Steer Clear of These 2 Troubled Stocks at CNBC
06:45PM  [video] You Ask, He Answers at CNBC
12:56PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of Upcoming Deadline - KERX GlobeNewswire
08:20AM  Programs by the FDA Designed to Speed Up Approval Process for Critical Drugs a Key Factor in Biotech's Industry Success Marketwire
07-Mar-13 09:20AM  6 gut checks before the stock market's opening bell at MarketWatch
08:34AM  6 gut checks before the stock market's opening bell at MarketWatch
07:10AM  6 gut checks before the stock market's opening bell at MarketWatch
03:45AM  Why one trader is selling Keryx puts optionMONSTER
05-Mar-13 09:50AM  3 Biotechs Still Burning Through Cash at Motley Fool
04-Mar-13 09:21AM  Today's Market News To Trade On: 5 Stocks Moving On News at Seeking Alpha
08:40AM  Weekly Stock Watch, Week Of March 4 at Seeking Alpha
07:14AM  Another Round On Keryx at Seeking Alpha
01-Mar-13 06:02PM  Nasdaq stocks posting largest percentage increases AP +11.82%
01:17PM  Nasdaq stocks posting largest percentage increases AP
11:41AM  Keryx takeover rumor driven by 'Sierra World Equity Review,' Feuerstein says theflyonthewall.com
10:55AM  Keryx takeover rumor driven by 'Sierra World Equity Review,' Feurstein says theflyonthewall.com
04:16AM  Best Performing U.S. Stocks YTD Through February at Seeking Alpha
28-Feb-13 11:07AM  Why Expect More Price Swings From These 4 Biotechs at TheStreet
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis. Zerenex is also in Phase II development for the management of phosphorus and iron deficiency in anemic patients with stages three to five non-dialysis dependent chronic kidney diseases. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Oliviero James F IIIChief Financial OfficerMay 13Sale8.3429,363244,887558,842May 14 07:00 PM
Oliviero James F IIIChief Financial OfficerApr 05Sale6.931,48410,284588,205Apr 08 06:01 PM
BENTSUR RONChief Executive OfficerApr 05Sale6.931,79512,439464,010Apr 08 06:02 PM
BENTSUR RONChief Executive OfficerMar 27Sale6.8831,231214,869465,805Mar 29 05:00 PM
BENTSUR RONChief Executive OfficerJan 04Sale2.746,01016,467497,036Jan 04 07:02 PM
Oliviero James F IIIChief Financial OfficerJan 04Sale2.7410,85929,754589,689Jan 04 07:01 PM
BENTSUR RONChief Executive OfficerOct 03Sale2.727462,029478,046Oct 05 07:02 PM
Oliviero James F IIIChief Financial OfficerOct 03Sale2.724,97313,527567,028Oct 05 07:01 PM
Oliviero James F IIIChief Financial OfficerJul 03Sale1.994,5599,072572,001Jul 06 07:01 PM
BENTSUR RONChief Executive OfficerJul 03Sale1.996841,361478,792Jul 06 07:01 PM